You are here:
Home
NICE Guidance
Conditions and diseases
Mental health, behavioural and neurodevelopmental conditions
Psychosis and schizophrenia
Schizophrenia: omega-3 fatty acid medicines
Evidence summary
Reference number:
ESUOM19
Published:
24 September 2013
Advice
Information for the public
Download (PDF)
Key points from the evidence
Overview for healthcare professionals
Relevance to NICE guidance programmes
Intervention and alternatives
Evidence review: efficacy
Evidence review: safety
Evidence review: economic issues
Evidence strengths and limitations
Summary for patients
References
Development of this evidence summary
Appendix: Search strategy and evidence selection
About 'Evidence summaries: unlicensed or off-label medicines'
Summary for patients
A
summary written for patients
is available on the NICE website.
Next page
References
Previous page
Evidence strengths and limitations
Back to top